The cellular uptake of amyloid-beta (Aβ) peptides represents a critical and multifaceted process in Alzheimer's disease (AD) pathogenesis that bridges extracellular plaque deposition and intracellular pathological changes. While Aβ accumulation in the brain has been extensively studied in the context of extracellular amyloid plaques, increasing evidence demonstrates that Aβ peptides actively enter various cell types within the brain parenchyma, including neurons, microglia, astrocytes, and endothelial cells, through multiple uptake mechanisms that profoundly influence disease progression [1].
Cellular Aβ uptake serves dual and seemingly contradictory roles in AD pathophysiology. On one hand, cellular internalization represents a protective clearance mechanism that removes toxic Aβ species from the extracellular space. On the other hand, intracellular Aβ accumulation triggers a cascade of pathological events including mitochondrial dysfunction, endosomal/lysosomal system impairment, oxidative stress, and ultimately neuronal death [2]. Understanding the molecular mechanisms governing Aβ uptake has therefore emerged as a crucial area for developing therapeutic interventions targeting AD progression.
This pathway page provides a comprehensive analysis of the molecular mechanisms mediating Aβ entry into different brain cell types, the intracellular trafficking pathways that determine Aβ fate, and the therapeutic implications of modulating these uptake processes.
| Receptor | Cell Type | Affinity | Function | Reference |
|---|---|---|---|---|
| LRP1 | Neurons, Astrocytes | High | Rapid endocytosis, clearance | [3] |
| RAGE | Multiple | Medium | Pro-inflammatory signaling | [4] |
| SR-A1 | Microglia | High | Phagocytosis | [5] |
| CD36 | Microglia, Neurons | Medium | Oxidative stress, inflammation | [6] |
| P-gp | Endothelial cells | Medium | Blood-brain barrier transport | [7] |
The Low-Density Lipoprotein Receptor-related Protein 1 (LRP1) is a major Aβ clearance receptor:
Receptor for Advanced Glycation End Products (RAGE):
CD36 (Cluster of Differentiation 36):
The class A scavenger receptor (SR-A1):
Microglia employ multiple phagocytic mechanisms[8]:
Once internalized, Aβ follows the endocytic pathway[10]:
The endosomal system is profoundly affected in AD, with early endosome enlargement being one of the earliest cellular hallmarks[11].
Aβ can be transported to mitochondria[12]:
Recent evidence suggests Aβ may enter the nucleus[13]:
When clearance is overwhelmed or dysregulated:
Laurin D, et al. "Cellular uptake of amyloid-beta peptides". Neurobiol Aging. 2022. ↩︎
Masliah E, et al. "Mechanisms of synaptic dysfunction in Alzheimer's disease". Acta Neuropathol. 2010. ↩︎
Vanmierlo M, et al. "LRP1 in Aβ metabolism and transport across the BBB". J Cereb Blood Flow Metab. 2021. ↩︎
Bharadwaj P, et al. "RAGE-mediated Aβ toxicity in neurons". Mol Neurobiol. 2020. ↩︎
Zhao Y, et al. "SR-A1 scavenger receptor and Aβ clearance in microglia". Glia. 2023. ↩︎
Hu Y, et al. "CD36 and oxidative stress in Aβ-treated microglia". Redox Biol. 2022. ↩︎
Zhang L, et al. "BBB transport of Aβ via LRP1 and P-gp". J Neurochem. 2022. ↩︎ ↩︎
Badell M, et al. "TREM2 variants affect microglial phagocytosis of Aβ". Neuron. 2018. ↩︎ ↩︎
Tai LM, et al. "ApoE opsonization enhances microglial Aβ phagocytosis". Neurobiol Dis. 2021. ↩︎
Laz尺ska D, et al. "Endosomal pathway in Aβ trafficking". Traffic. 2019. ↩︎
Park H, et al. "Early endosome enlargement in AD models". Nat Commun. 2024. ↩︎ ↩︎
Yuan Z, et al. "Aβ transport to mitochondria and mitochondrial dysfunction". Mol Cell Neurosci. 2016. ↩︎
Ullah M, et al. "Aβ nuclear import and gene expression modulation". Aging Cell. 2024. ↩︎
Candas D, et al. "Lysosomal dysfunction in Alzheimer's disease". Acta Neuropathol. 2019. ↩︎
Fein J, et al. "Autophagy and Aβ clearance in neurodegeneration". Nat Rev Neurosci. 2021. ↩︎
Schrader T, et al. "Neprilysin and IDE in Aβ degradation". Curr Alzheimer Res. 2020. ↩︎
Choi J, et al. "Cathepsin release from damaged lysosomes". Cell Death Discov. 2023. ↩︎
Mullan G, et al. "Prion-like spread of Aβ pathology". Brain. 2022. ↩︎